{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:51:13Z","timestamp":1791427873172,"version":"4.3.3"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000297","name":"Royal College of Surgeons of England","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eururo.2026.09.001","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:09:24Z","timestamp":1791320964000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial"],"prefix":"10.1016","author":[{"given":"Omar","family":"El-Taji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dutey-Magni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mick","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macey","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Amos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Sydes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel W.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7359-7114","authenticated-orcid":false,"given":"Ashwin","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.09.001_b0005","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.09.001_b0010","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, Zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.09.001_b0015","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.09.001_b0020","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.09.001_b0025","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.09.001_b0030","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.09.001_b0035","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.09.001_b0040","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"Arches: a randomized, phase 3 study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.09.001_b0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.09.001_b0050","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.09.001_b0055","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.09.001_b0060","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","article-title":"Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis","volume":"10","author":"El-Taji","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.09.001_b0065","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.urolonc.2019.10.006","article-title":"Improving research for prostate cancer survivorship: a statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group","volume":"38","author":"Narayan","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.09.001_b0070","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review","volume":"21","author":"Bosco","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.eururo.2026.09.001_b0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","article-title":"Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85\u201331","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.09.001_b0080","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/JU.0000000000000714","article-title":"Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study","volume":"203","author":"Leong","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.09.001_b0085","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.eururo.2026.09.001_b0090","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eururo.2026.09.001_b0095","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00345-024-04852-2","article-title":"Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network","volume":"42","author":"Merseburger","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.09.001_b0100","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europ","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eururo.2026.09.001_b0105","doi-asserted-by":"crossref","unstructured":"SCORE2-OP working group and ESC cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J 2021;42:2455\u201367.","DOI":"10.1093\/eurheartj\/ehab312"},{"key":"10.1016\/j.eururo.2026.09.001_b0110","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/ije\/dyx015","article-title":"Data resource profile: hospital episode statistics admitted patient care (HES APC)","volume":"46","author":"Herbert","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.eururo.2026.09.001_b0115","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1016\/S2589-7500(22)00122-4","article-title":"Data provenance and integrity of health-care systems data for clinical trials","volume":"4","author":"Murray","year":"2022","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.eururo.2026.09.001_b0120","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.annonc.2025.07.005","article-title":"Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase 3 trials of docetaxel and zoledronic acid using healthcare systems data","volume":"36","author":"Jones","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.09.001_b0125","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2147\/CLEP.S265619","article-title":"Validity of acute cardiovascular outcome diagnoses recorded in European electronic health records: a systematic review","volume":"12","author":"Davidson","year":"2020","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.eururo.2026.09.001_b0130","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2350","article-title":"Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study","volume":"346","author":"Herrett","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.09.001_b0135","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/ehf2.14669","article-title":"Identification of heart failure hospitalization from NHS Digital data: comparison with expert adjudication","volume":"11","author":"Soltani","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.eururo.2026.09.001_b0140","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/eurheartj\/ehu207","article-title":"Towards better clinical prediction models: seven steps for development and an ABCD for validation","volume":"35","author":"Steyerberg","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eururo.2026.09.001_b0145","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1002\/sim.5958","article-title":"Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks","volume":"32","author":"Blanche","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.eururo.2026.09.001_b0150","first-page":"4","article-title":"Cardiovascular toxicities of androgen deprivation therapy in Asian men with localized prostate cancer after curative radiotherapy: a registry-based observational study","volume":"8","author":"Li","year":"2022","journal-title":"Cardiooncology"},{"key":"10.1016\/j.eururo.2026.09.001_b0155","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.09.001_b0160","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/eurjpc\/zwad318","article-title":"Validation of Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in the EPIC-Norfolk prospective population cohort","volume":"31","author":"van Trier","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.eururo.2026.09.001_b0165","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/2988289","article-title":"Patient demographics and major adverse cardiovascular events after androgen deprivation therapy for prostate cancer","volume":"2024","author":"Wallis","year":"2024","journal-title":"Adv Urol"},{"key":"10.1016\/j.eururo.2026.09.001_b0170","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.clgc.2014.12.003","article-title":"Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study","volume":"13","author":"Gandaglia","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.09.001_b0175","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.eururo.2026.09.001_b0180","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/MOU.0000000000000675","article-title":"Prostate radiotherapy in newly diagnosed metastatic prostate cancer","volume":"29","author":"Ali","year":"2019","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2026.09.001_b0185","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.clgc.2024.01.014","article-title":"Incidental coronary arterial calcification for cardiovascular risk assessment in men with prostate cancer undergoing PET\/CT imaging","volume":"22","author":"Shaikh","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.09.001_b0190","doi-asserted-by":"crossref","DOI":"10.1200\/OP-25-00506","article-title":"Evaluating clinical tools to monitor cardiovascular risk in men with prostate cancer receiving hormone therapy","author":"Venkatesh","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.eururo.2026.09.001_b0195","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2025.43.5_suppl.20","article-title":"Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD)","volume":"43","author":"Fisher","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.09.001_b0200","unstructured":"National prostate cancer audit (NPCA). State of the nation report October 2025. London; 2025."},{"key":"10.1016\/j.eururo.2026.09.001_b0205","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.eururo.2026.09.001_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1494073","article-title":"The value of real world evidence and pragmatic trials in advanced prostate cancer- insights from the electronic Prostate Cancer Australian and Asian Database","volume":"14","author":"Anton","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2026.09.001_b0215","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jamaoncol.2018.5953","article-title":"Association of patient comorbid conditions with cancer clinical trial participation","volume":"5","author":"Unger","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.09.001_b0220","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/bjc.2016.162","article-title":"Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee","volume":"115","author":"Turner","year":"2016","journal-title":"Br J Cancer"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826023705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826023705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:29:50Z","timestamp":1791426590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826023705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"alternative-id":["S0302283826023705"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.09.001","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}